Entera Bio (ENTX) Cash from Investing Activities (2021 - 2025)
Entera Bio (ENTX) recorded quarterly Cash from Investing Activities of -$27000.0 in Q4 2025, up 37.21% on a QoQ basis from -$43000.0 in Q3 2025, and down 800.0% year-over-year from $3857.1 in Q4 2024.
Entera Bio (ENTX) Cash from Investing Activities (2021 - 2025) Analysis & Trends
Entera Bio has disclosed Cash from Investing Activities across 5 years of filings, most recently posting -$27000.0 for Q4 2025.
- Quarterly Cash from Investing Activities fell 800.0% year-over-year to -$27000.0 in Q4 2025, while the trailing twelve-month figure through Mar 2026 was -$99000.0 (down 800.0% YoY) and the FY2025 annual result came in at -$107000.0, down 3466.67% from the prior year.
- Cash from Investing Activities improved to -$27000.0 in Q4 2025, from -$43000.0 in the prior quarter.
- Over five years, Cash from Investing Activities peaked at -$1000.0 in Q2 2023 and troughed at -$57000.0 in Q3 2022.
- A 5-year average of -$17571.4 and a median of -$10500.0 in 2021 frame the typical range for Cash from Investing Activities.
- Annual changes were most pronounced in 2023 — Cash from Investing Activities jumped 94.74% — and 2025, when it plunged 800.0%.
- Tracing ENTX's Cash from Investing Activities over 5 years: stood at -$10000.0 in 2021, then jumped by 70.0% to -$3000.0 in 2022, then plunged by 66.67% to -$5000.0 in 2023, then soared by 40.0% to -$3000.0 in 2024, then tumbled by 800.0% to -$27000.0 in 2025.
- Business Quant data shows ENTX's Cash from Investing Activities at -$27000.0 in Q4 2025, -$43000.0 in Q3 2025, and -$29000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | -2.89 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 638.50 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | -431.90 Mn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | 579,519.10 |
| 10 | Entera Bio | 57.79 Mn | 53.65 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -27,000.00 |
| Dec 31, 2025 | -27,000.00 |
| Sep 30, 2025 | -43,000.00 |
| Sep 30, 2025 | -43,000.00 |
| Jun 30, 2025 | -29,000.00 |
| Jun 30, 2025 | -29,000.00 |
| Mar 31, 2025 | -8,000.00 |
| Mar 31, 2025 | -8,000.00 |
| Dec 31, 2024 | -3,000.00 |
| Dec 31, 2024 | -3,000.00 |
| Dec 31, 2023 | -5,000.00 |
| Dec 31, 2023 | -5,000.00 |
| Jun 30, 2023 | -1,000.00 |
| Jun 30, 2023 | -1,000.00 |
| Mar 31, 2023 | -11,000.00 |
| Mar 31, 2023 | -11,000.00 |
| Dec 31, 2022 | -3,000.00 |
| Dec 31, 2022 | -3,000.00 |
| Sep 30, 2022 | -57,000.00 |
| Sep 30, 2022 | -57,000.00 |